OPKO Health, Inc. (OPK)
Nasdaq · Healthcare · Diagnostics & Research
$1.57+0.64%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.2B
- 52-week range
- $0.98 – $1.75
- 52-week change
- +1.30%
- EPS (trailing)
- −$0.09
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $607M (−14.90%)
- Net income
- −$226B
- Operating margin
- −19.3%
- Diluted EPS
- −$0.30
- Free cash flow
- −$191M
From the company’s annual report on SEC EDGAR.
About OPKO Health, Inc.
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency.
Headquarters: Miami, United States · 2,275 employees · opko.com